戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ations, and established the effectiveness of enzyme therapy.
2 ant given the advent of specific replacement enzyme therapy.
3 2 years of high-dose (50 U/kg every 2 weeks) enzyme therapy.
4   Three patients have elected to discontinue enzyme therapy.
5 teoblasts can be corrected by asfotase-alpha enzyme therapy aimed at reducing PPi concentration.
6 g the lowering of adenosine levels using ADA enzyme therapy and also through the use of the adenosine
7 l be useful in examining the efficacy of ADA enzyme therapy and studying the mechanisms underlying th
8 ement has provided impetus for design of new enzyme therapies, and creation of substrate depletion an
9 that included high-calorie diets, pancreatic-enzyme therapy, and fat-soluble vitamin supplements.
10 the toxicity of gliadin and open the way for enzyme therapy as an adjunct to the gluten free diet.
11 st lysosomal storage disease (LSD) for which enzyme therapy became available, and although infusions
12 osine and 2'-deoxyadenosine levels using ADA enzyme therapy decreased the pulmonary eosinophilia and
13                       Two patients receiving enzyme therapy developed neutralizing antibodies to acid
14                                          ADA enzyme therapy diminished the IL-13-induced increase in
15 ld be valuable also in future development of enzyme therapies for other drugs of abuse.
16 g antibodies to acid beta-glucosidase during enzyme therapy for Gaucher disease has significant impli
17                                              Enzyme therapy for lysosomal storage disorders directed
18 he considerable expense and inconvenience of enzyme therapy for patients, renders the search for alte
19 hat BL-1118 is a promising second generation enzyme therapy for PXE, the first generation of which is
20                    The advent of efficacious enzyme therapy has emphasized the importance of early di
21                                              Enzyme therapy has led to improvements in physical and f
22 thoracoscopic surgery (VATS) or intrapleural enzyme therapy (IET) in pleural infection requires a pha
23    These studies provide feasibility for LAL enzyme therapy in human WD and CESD.
24 , eliglustat was noninferior to imiglucerase enzyme therapy in maintaining stable platelet counts, he
25                                          ADA enzyme therapy in these mice normalized cochlear adenosi
26 rosis (CF), even with replacement pancreatic enzyme therapy, is often associated with decreased carot
27 ing ADA-deficient mice on low dosages of ADA enzyme therapy led to chronic elevations in lung adenosi
28 n, which was unresponsive to oral pancreatic enzyme therapy or a gluten-free diet.
29                    Lowering adenosine by ADA enzyme therapy or genetic deletion of ADORA2B significan
30 herapy-group patients were alive, and 16% of enzyme-therapy patients were alive.
31                                 A "low-dose" enzyme therapy protocol prevented the pulmonary phenotyp
32                                A "high-dose" enzyme therapy protocol resulted in decreased metabolic
33                            Additionally, ADA enzyme therapy rescued SNHL by restoring nerve fiber str
34                              ADA replacement enzyme therapy resulted in a lowering of adenosine level
35 s that chronic reduction of adenosine by ADA enzyme therapy successfully attenuated penile fibrosis i
36                                          ADA enzyme therapy successfully corrected the priapic activi
37 ic diseases that are candidates for gene and enzyme therapies such as messenger RNA (mRNA)-mediated p
38 e 2 initially showed a favorable response to enzyme therapy that plateaued after 1 year of treatment.
39    The ability to safely and effectively use enzyme therapy to inhibit or reverse visceral-disease pr
40                          Moreover, using ADA enzyme therapy to reduce adenosine or a specific antagon
41 ) of lysosomal acid lipase and its use as an enzyme therapy to reduce atherosclerotic lesions in a mo
42 , phase III, controlled trial of proteolytic enzyme therapy versus chemotherapy.
43                                              Enzyme therapy was discontinued in case 1, with resultan
44 ed donor (URD) BMT as a vehicle for adoptive enzyme therapy was evaluated in this retrospective study
45                            The potential for enzyme therapy was tested using mannose terminated human
46                                          ADA enzyme therapy was used to examine the relative impact o
47 lumbia University, and patients who received enzyme therapy were seen by the participating alternativ
48 GD type 1 (age range, 18-50 years) receiving enzyme therapy who were randomized for this study.